A Phase 1, Open-label, Safety and Pharmacokinetic Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Rucaparib (Primary)
- Indications Breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Acronyms RUCA-J
- Sponsors Clovis Oncology
- 03 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2019 According to a Clovis media release, the recommended dose of rucaparib for this study has identified as 600 mg BID.
- 06 Mar 2018 New trial record